<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002366</url>
  </required_header>
  <id_info>
    <org_study_id>245C</org_study_id>
    <secondary_id>M95-320</secondary_id>
    <nct_id>NCT00002366</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma</brief_title>
  <official_title>A Phase II Safety and Activity Study of Ritonavir in the Treatment of HIV-Associated Cutaneous Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and anti-Kaposi's sarcoma activity of ritonavir.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Sarcoma, Kaposi</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Patients may receive oral acyclovir and may continue prophylactic treatment for PCP,&#xD;
             fungal infection, MAC and toxoplasmosis.&#xD;
&#xD;
          -  Topical treatment and intralesional chemotherapy will be allowed for lesions which&#xD;
             will not be used as indicator or biopsy lesions.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Localized radiotherapy will be allowed for lesions which will not be used as indicator or&#xD;
        biopsy lesions.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documentation of a positive ELISA test for HIV with a confirmatory test.&#xD;
&#xD;
          -  Biopsy proven, cutaneous or oropharyngeal Kaposi's sarcoma.&#xD;
&#xD;
          -  Vital signs, physical examination and laboratory assessments that exhibit no evidence&#xD;
             of an acute illness.&#xD;
&#xD;
          -  Patients must agree to report all current medications to the primary investigator and&#xD;
             obtain prior permission to use them when feasible.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Evidence of pulmonary Kaposi's sarcoma.&#xD;
&#xD;
          -  Positive urine screen for recreational drugs.&#xD;
&#xD;
          -  Current participation in another antiviral research study.&#xD;
&#xD;
          -  Investigator anticipates poor patient compliance with the protocol.&#xD;
&#xD;
          -  Patient has any condition that, in the investigator's opinion, may obscure the proper&#xD;
             observation of the safety or activity of ritonavir.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral therapy.&#xD;
&#xD;
          -  Protease inhibitor therapy.&#xD;
&#xD;
          -  Antiviral agent (e.g., oral ganciclovir or Foscarnet) or prophylactic medication for&#xD;
             an AIDS defining illness which the patient cannot be removed from.&#xD;
&#xD;
          -  Chemotherapy for Kaposi's sarcoma.&#xD;
&#xD;
          -  Treatment with any medications that may interact with ritonavir.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Radiotherapy for Kaposi's sarcoma.&#xD;
&#xD;
        Patients with any of the following prior conditions are excluded:&#xD;
&#xD;
          -  History of psychiatric illness which is currently medically significant.&#xD;
&#xD;
          -  History of pancreatitis.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  All antiretroviral therapy within 2 weeks prior to the start of the treatment phase of&#xD;
             the study.&#xD;
&#xD;
          -  Systemic chemotherapy of interferon within 30 days prior to study entry.&#xD;
&#xD;
          -  Previous treatment with a protease inhibitor.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Active substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prince Henry's Hosp / Med Oncology</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent's Hosp Med Centre</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Carr A, Milliken S, Lewis C, Mitsuyasu R, Miles S, Newell M, Cooper DA. A pilot phase II safety and activity study of ritonavir in the treatment of HIV-associated cutaneous Kaposi's sarcoma. Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:194 (abstract no 703)</citation>
  </reference>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>February 19, 2009</last_update_submitted>
  <last_update_submitted_qc>February 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2009</last_update_posted>
  <keyword>Skin Neoplasms</keyword>
  <keyword>Sarcoma, Kaposi</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Ritonavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

